Home › Cancer (all types) › NCT06643884
Suprachoroidal Administration in Subjects With Metastases to the Choroid
RecruitingPhase 2
A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor. * Have at least one Metastases to the Choroid in the study eye Exclusion Criteria: * Active ocular infection or disease. * Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment. * Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment
About the study
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
What is being tested
- AU-011 (drug)
- SCS Microinjector (device)
- Laser (device)
Sponsor: Aura Biosciences · Participants: 24 · Started: Dec 16, 2024
Contact the study team
- Medical Monitor · Phone: 617-500-8864
Official record on ClinicalTrials.gov — NCT06643884
Locations in the U.S.
| California | Byers Eye Institute at Stanford University, Palo Alto |
| Florida | Bascom Palmer Eye Institute, Miami |
| Massachusetts | Massachusetts Eye and Ear, Boston |
| Michigan | Kellogg Eye Center, Ann Arbor |
| Minnesota | Mayo Clinic, Rochester (Not yet recruiting) |
| Ohio | Cleveland Clinic, Cole Eye Institute, Cleveland (Not yet recruiting) |
| Pennsylvania | Shields and Shields, PC, Philadelphia (Not yet recruiting) |
| Tennessee | Tennessee Retina, PC, Nashville |
| Texas | Retina Consultants of Texas, Bellaire |
| Washington | University of Washington, Seattle |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.